FDA Brief

Warning letters Drugs

FDA warning letter to

Medgel Private Limited

High riskIssued Jul 20, 2023Posted Aug 1, 2023Center for Drug Evaluation and Research | CDER

FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.

What happened

FDA inspected Medgel's Pithampur facility from January 23 to 27, 2023. It found inadequate investigations of out-of-specification (OOS) assay results and humidity excursions, quality control unit oversight failures, data integrity lapses such as shared usernames and deleted raw data, and missing diethylene glycol/ethylene glycol testing for certain components. FDA said Medgel's February 17, 2023 response was inadequate.

What FDA found

  1. Medgel invalidated out-of-specification assay results and released a batch after retesting without an adequate scientific justification or thorough investigation.

    21 CFR 211.192
  2. Medgel did not adequately investigate humidity excursions in production and stability chambers, and its humidity raw data was not backed up and was deleted monthly.

    21 CFR 211.192
  3. Medgel's quality control unit failed to control batch records, CGMP documentation, laboratory data, instrument access, and audit trails, including use of shared usernames and passwords.

    21 CFR 211.22
  4. Medgel did not test each component lot for identity and purity, including diethylene glycol and ethylene glycol limits for glycerin, propylene glycol, sorbitol solution, and polyethylene glycol, and accepted some API supplier certificates without impurity testing.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  5. Medgel destroyed microbiological plates before recording the data, did not contemporaneously document laboratory data, and did not adequately review raw data and audit trails.

    21 CFR 211.22

What FDA wants

FDA asks Medgel to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence, including the requested OOS, data integrity, and component-testing reviews and risk assessments. FDA also strongly recommends a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC capsules from this contract manufacturer
  • U.S. importers and distributors of Medgel drug products
  • supplier quality teams auditing Indian drug manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk